Cellyan Biotechnology CO., LTD (HKPD) — SEC Filings
Latest SEC filings for Cellyan Biotechnology CO., LTD. Recent EFFECT filing on Apr 9, 2026. AI-decoded analysis of earnings, risk factors, and insider trad
View Cellyan Biotechnology CO., LTD on SEC EDGAR
Overview
Cellyan Biotechnology CO., LTD (HKPD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 31, 2025: Cellyan Biotechnology Co., Ltd. (formerly Hong Kong Pharma Digital Technology Holdings Ltd) filed a Form 6-K on December 31, 2025, for the month of December 2025. The company, incorporated in E9 with a fiscal year end of March 31, is a wholesale distributor of proprietary drugs and druggists' sundri
Sentiment Summary
Across 10 filings, the sentiment breakdown is: 10 neutral. The dominant filing sentiment for Cellyan Biotechnology CO., LTD is neutral.
Filing Type Overview
Cellyan Biotechnology CO., LTD (HKPD) has filed 1 EFFECT, 8 6-K, 1 20-F with the SEC between Jan 2025 to Apr 2026.
Filings by Year
Recent Filings (10)
- EFFECT Filing — EFFECT · Apr 9, 2026
-
Cellyan Biotechnology Files 6-K for December 2025
— 6-K · Dec 31, 2025 Risk: low
Cellyan Biotechnology Co., Ltd. (formerly Hong Kong Pharma Digital Technology Holdings Ltd) filed a Form 6-K on December 31, 2025, for the month of December 202 -
Hong Kong Pharma Digital Digital Tech Files 6-K: Material Info Update
— 6-K · Dec 17, 2025
Hong Kong Pharma Digital Technology Holdings Ltd. filed a 6-K, which is a foreign private issuer report, indicating they are providing information that is mater -
Hong Kong Pharma Digital Files 6-K, Maintains SEC Compliance
— 6-K · Nov 24, 2025
Hong Kong Pharma Digital Technology Holdings Ltd. filed a 6-K, which is a report for foreign private issuers, indicating they are providing information that wou -
Hong Kong Pharma Directors Resign
— 6-K · Nov 12, 2025 Risk: medium
Hong Kong Pharma Digital Technology Holdings Limited announced on November 6, 2025, that its Board of Directors received resignations from two independent direc -
Hong Kong Pharma CEO, CFO, COO Resign
— 6-K · Oct 7, 2025 Risk: medium
Hong Kong Pharma Digital Technology Holdings Limited announced on October 6, 2025, the resignation of its Chief Executive Officer, Chief Financial Officer, and -
Hong Kong Pharma Appoints New Independent Director
— 6-K · Sep 11, 2025 Risk: low
Hong Kong Pharma Digital Technology Holdings Limited announced on September 9, 2025, the appointment of Mr. Zhou Mike Yao as an independent director to its Boar -
Hong Kong Pharma Files 2025 Annual Report
— 20-F · Aug 14, 2025 Risk: low
Hong Kong Pharma Digital Technology Holdings Ltd filed its annual report on Form 20-F for the fiscal year ended March 31, 2025. The company, primarily involved -
Hong Kong Pharma Files 6-K for March 2025
— 6-K · Mar 28, 2025 Risk: low
Hong Kong Pharma Digital Technology Holdings Limited filed a Form 6-K on March 28, 2025, reporting for the month of March 2025. The company, incorporated in E9, -
Hong Kong Pharma Enters Underwriting Agreement
— 6-K · Jan 17, 2025 Risk: medium
On January 14, 2025, Hong Kong Pharma Digital Technology Holdings Limited entered into an Underwriting Agreement with Bancroft Capital, LLC. This agreement outl
Risk Profile
Risk Assessment: Of HKPD's 7 recent filings, 0 were flagged as high-risk, 3 as medium-risk, and 4 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Mr. Zhou Mike Yao
- Lap Sun Wong
Top Tags
6-K (2) · foreign-private-issuer (2) · foreign-issuer (2) · sec-filing (2) · disclosure (1) · corporate-update (1) · material-information (1) · compliance (1) · regulatory-filing (1) · director-resignation (1)
Key Numbers
- Fiscal Year End: 0331 — Indicates the end of the reporting period for financial statements.
Frequently Asked Questions
What are the latest SEC filings for Cellyan Biotechnology CO., LTD (HKPD)?
Cellyan Biotechnology CO., LTD has 10 recent SEC filings from Jan 2025 to Apr 2026, including 8 6-K, 1 EFFECT, 1 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of HKPD filings?
Across 10 filings, the sentiment breakdown is: 10 neutral. The dominant sentiment is neutral.
Where can I find Cellyan Biotechnology CO., LTD SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cellyan Biotechnology CO., LTD (HKPD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cellyan Biotechnology CO., LTD?
Financial highlights for Cellyan Biotechnology CO., LTD are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for HKPD?
Investment thesis data for HKPD will be available once enriched filings are processed.
Who are the key executives at Cellyan Biotechnology CO., LTD?
Key executives identified across Cellyan Biotechnology CO., LTD's filings include Mr. Zhou Mike Yao, Lap Sun Wong.
What are the main risk factors for Cellyan Biotechnology CO., LTD stock?
Of HKPD's 7 assessed filings, 0 were flagged high-risk, 3 medium-risk, and 4 low-risk.
What are recent predictions and forward guidance from Cellyan Biotechnology CO., LTD?
Forward guidance and predictions for Cellyan Biotechnology CO., LTD are extracted from SEC filings as they are enriched.